Partial response of hepatocellular carcinoma to lenalidomide following progression in response to lenvatinib: A case report
Authors:
Open Access
- 5 July 2024
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 28 (3) , 1-5
Abstract
Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer. Although it has a high mortality rate, there is currently no effective treatment for HCC. Lenvatinib has traditionally been used as the first‑line treatment for advanced HCC (aHCC); however, resistance to this therapy is common. It can be difficult to select effective second‑line drugs to overcome lenvatinib resistance when treating aHCC. For patients with aHCC, poor treatment efficacy can result in patients missing the optimal treatment window and can lead to an irreversible situation. Lenalidomide has begun to be used to treat HCC; however, to the best of our knowledge, its efficacy in patients with lenvatinib‑resistant HCC remains to be reported on in the literature. The present case report, to the best of our knowledge, describes the first case in the literature of a patient with lenvatinib‑resistant aHCC who achieved a partial response after the treatment regimen was switched to lenalidomide. The present case report provides a promising novel route for the treatment of lenvatinib‑resistant HCC.Keywords
This publication has 22 references indexed in Scilit:
- Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular CarcinomaCurrent Medicinal Chemistry, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Lenvatinib for Hepatocellular Carcinoma: A Literature ReviewPharmaceuticals, 2021
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- FACT‐Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance StatusLiver International, 2018
- Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular CarcinomaThe Oncologist, 2016
- Potential synergistic anti‐tumor activity between lenalidomide and sorafenib in hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2014
- Clinical Trials in Hepatocellular Carcinoma: An UpdateLiver Cancer, 2013
- The parallel lives of angiogenesis and immunosuppression: cancer and other talesNature Reviews Immunology, 2011
- Lenalidomide mode of action: linking bench and clinical findingsBlood Reviews, 2010